fludarabine has been researched along with transforming growth factor beta in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beyer, M; Darabi, K; Debey, S; Endl, E; Hallek, M; Jensen, M; Knolle, PA; Kochanek, M; Popov, A; Schultze, JL; Thomas, RK; von Bergwelt-Baildon, M | 1 |
| Alexander, S; Ballen, KK; Dey, BR; Dombkowski, D; McAfee, S; Means, TK; Preffer, FI; Sachs, DH; Saidman, S; Shaffer, J; Spitzer, TR; Sykes, M; Villard, J | 1 |
2 other study(ies) available for fludarabine and transforming growth factor beta
| Article | Year |
|---|---|
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.
Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation; Case-Control Studies; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CTLA-4 Antigen; DNA-Binding Proteins; Forkhead Transcription Factors; Glucocorticoid-Induced TNFR-Related Protein; Humans; Interleukin-10; L-Selectin; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Receptors, Interleukin-2; Receptors, Nerve Growth Factor; Receptors, Tumor Necrosis Factor; T-Lymphocyte Subsets; Transforming Growth Factor beta; Transforming Growth Factor beta1; Vidarabine | 2005 |
Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation; CD2 Antigens; CTLA-4 Antigen; Forkhead Transcription Factors; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Interferon-gamma; T-Lymphocytes, Regulatory; Transforming Growth Factor beta; Transplantation Chimera; Vidarabine | 2007 |